Administration
An integrated regimen
*When used with LYNPARZA, the recommended dose of bevacizumab is 15 mg/kg every 3 weeks. Refer to the Prescribing Information for bevacizumab when used in combination with LYNPARZA for more information.1
Per PAOLA-1 protocol:
The recommended daily dose of LYNPARZA is:
300 mg (two 150-mg tablets) taken orally twice daily, with or without food (total 600 mg daily)
Consider dose interruption if a patient experiences an AR.
See the complete Prescribing Information for detailed dose interruption instructions for select ARs
If an AR continues after restarting LYNPARZA following dose interruption, consider dose reduction:
INITIAL REDUCTION
Initial reduction to 250 mg
(one 150-mg tablet and one 100-mg tablet) taken twice daily (total 500 mg daily)
FINAL REDUCTION
Final reduction to 200 mg
(two 100-mg tablets) taken twice daily (total 400 mg daily)
Please refer to the bevacizumab package insert for more information on the management of ARs related to bevacizumab and bevacizumab dose adjustments.
Please refer to the Prescribing Information for bevacizumab when used in combination with LYNPARZA for recommended
AR=adverse reaction; HRD=homologous recombination deficiency; PARP=poly (ADP-ribose) polymerase.
This website contains management strategies for some of the most common adverse reactions associated with LYNPARZA. Your patients may experience other side effects than the ones listed here.
The strategies offered here are not meant to replace your clinical judgment.
Please refer to the full Prescribing Information for additional safety information about LYNPARZA.
The National Cancer Institute (NCI) defines the grades for anemia9
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Hemoglobin (Hgb) <LLN - 10.0 g/dL; <LLN - 6.2 mmoI/L; <LLN - 100 g/L |
| 2 | Hgb <10.0 - 8.0 g/dL; <6.2 - 4.9 mmoI/L; <100 - 80 g/L |
| 3 | Hgb <8.0 g/dL; <4.9 mmoI/L; <80 g/L; transfusion indicated |
| 4 | Life-threatening consequences; urgent intervention indicated |
| 5 | Death |
| PRESENTATION | |
| A disorder characterized by a reduction in the amount of hemoglobin in 100 mL of blood. Signs and symptoms of anemia may include pallor of the skin and mucous membranes, shortness of breath, palpitations of the heart, soft systolic murmurs, lethargy, and fatigability. | |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
Consider managing with transfusions10
If transfusions do not resolve the AR: Consider dose interruption —Restart treatment at lower dose when anemia is Grade ≤1 within a maximum of 28 days1,10
Depending on the duration and severity of the AR, dose modification or discontinuation may be necessary1,10:
If event grade is ≤1 within a maximum of 28 days, consider dose modification:
If event grade is >2 after 28 days and the patient has already undergone 2 dose reductions (to a minimum of 100 mg twice daily)10:
CTCAE=Common Terminology Criteria for Adverse Events; LLN=lower limit of normal.
The NCI defines the grades for constipation9
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Occasional or intermittent symptoms; occasional use of stool softeners, laxatives, dietary modification, or enema |
| 2 | Persistent symptoms with regular use of laxatives or enemas; limiting instrumental ADL |
| 3 | Obstipation with manual evacuation indicated; limiting self-care ADL |
| 4 | Life-threatening consequences; urgent intervention indicated |
| 5 | Death |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
REMEMBER TO EVALUATE CONCOMITANT MEDICATIONS THAT MAY CONTRIBUTE TO CONSTIPATION.11
ADL=activities of daily living.
The NCI defines the grades for diarrhea9
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Increase of 1–3 stools per day over baseline; mild increase in ostomy output compared with baseline |
| 2 | Increase of 4–6 stools per day over baseline; moderate increase in ostomy output compared with baseline; limiting instrumental ADL |
| 3 | Increase of ≥7 stools per day over baseline; hospitalization indicated; severe increase in ostomy output compared with baseline; limiting self-care ADL |
| 4 | Life-threatening consequences; urgent intervention indicated |
| 5 | Death |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
Consider dose interruption
Restart treatment at same or lower dose when symptoms are Grade ≤1 or at a maximum of 4 weeks1,15-19
Consider dose modification1,15:
The NCI defines the grades for dysgeusia9,20
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Altered taste but no change in diet |
| 2 | Altered taste with change in diet (eg, oral supplements); noxious or unpleasant taste; loss of taste |
| PRESENTATION | |
| Impaired or distorted ability to taste. Severity depends on extent of impairment and resultant changes in dietary habits. | |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
Consider dose interruption
Restart treatment at lower dose when dysgeusia is Grade ≤1 within a maximum of 4 weeks1,10,16-19
Consider dose modification1,10:
If event grade is ≤1 within a maximum of 28 days, consider dose modification:
The NCI defines the grades for dyspepsia and abdominal pain9,22
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Mild symptoms; intervention not indicated |
| 2 | Moderate symptoms; medical intervention indicated |
| 3 | Severe symptoms; operative intervention indicated |
| PRESENTATION | |
| Sensation of pain or discomfort in the upper abdomen or lower chest following eating. May be accompanied by heartburn, flatulence, or nausea. Severity of symptoms directly correlated with NCI CTCAE grade. | |
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Mild pain |
| 2 | Moderate pain; limiting instrumental ADL |
| 3 | Severe pain; limiting self-care ADL |
| PRESENTATION | |
| A disorder characterized by a sensation of marked discomfort in the abdominal region. | |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
Consider referring patients to a gastroenterologist15
Consider dose interruption
Restart treatment at same or lower dose when symptoms are back to baseline or at a maximum of 4 weeks1,15-19
Consider dose modification1,15:
The NCI defines the grades for fatigue9,22
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Fatigue relieved by rest |
| 2 | Fatigue not relieved by rest; limiting instrumental ADL |
| 3 | Fatigue not relieved by rest; limiting self-care ADL |
| PRESENTATION | |
| Lack of strength brought on by mental or physical activity and associated with a range of symptoms, including muscle pain, headaches, poor sleep, disturbed moods, and impaired concentration. | |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
Consider dose interruption
Allow fatigue to return to baseline1,15
Resume therapy
At ≤4 weeks, resume previous dose15-19
If symptoms are severe, consider dose modification1,15:
The NCI defines the grades for headache9,24
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Mild pain |
| 2 | Moderate pain; limiting instrumental ADL |
| 3 | Severe pain; limiting self-care ADL |
| PRESENTATION | |
| Bilateral pressure of varying severity—may exhibit increased sensitivity to pressure and electrical/thermal stimuli. Determination of severity is dependent on degree of pain and resultant disruptions in patients' daily activities. |
|
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
AVOID PRESCRIBING OPIATES/BARBITURATES FOR PATIENTS WHO ARE EXPERIENCING MIGRAINE HEADACHES AS THESE MEDICATIONS ARE NOT PREFERRED AGENTS FOR THE TREATMENT OF HEADACHE.27
The NCI defines the grades for nausea and vomiting9
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Loss of appetite without alteration in eating habits |
| 2 | Oral intake decreased without significant weight loss, dehydration, or malnutrition |
| 3 | Inadequate oral caloric or fluid intake; tube feeding, total parenteral nutrition (TPN), or hospitalization indicated |
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | Intervention not indicated |
| 2 | Outpatient IV hydration; medical intervention indicated |
| 3 | Tube feeding, TPN, or hospitalization indicated |
| 4 | Life-threatening consequences |
| 5 | Death |
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
*Refer to the NCCN Guidelines® for specific treatment recommendations; not all agents in a drug class are recommended.
†The general principle of breakthrough treatment is to add one agent from a different drug class to the current antiemetic regimen. For uncontrolled nausea and vomiting, clinicians can reevaluate and consider dose adjustments and/or sequentially add one agent from a different drug class.28
Consider dose interruption
Hold dose until symptoms have returned to baseline for a day or two (no longer than 4 weeks)1,15-19
Resume therapy
May permit successful reintroduction of LYNPARZA at the same dose15
Perform a clinical evaluation
Confirm there are no secondary aggravating factors and ensure that nausea/vomiting therapy is optimized15
Consider dose modification1:
See NCCN Guidelines for Antiemesis for recommendations about uncontrolled nausea and vomiting.28
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
The NCI defines the grades for neutropenia9,30
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | <LLN - 1500/mm3; <LLN - 1.5 x 109/L |
| 2 | <1500 - 1000/mm3; <1.5 - 1.0 x 109/L |
| 3 | <1000 - 500/mm3; <1.0 - 0.5 x 109/L |
| 4 | <500/mm3; <0.5 x 109/L |
| 5 | ------------------------------------------------- |
| NCI CTCAE GRADE | DESCRIPTION |
|---|---|
| 1 | ------------------------------------------------- |
| 2 | ------------------------------------------------- |
| 3 | ANC <1000/mm3 and a single temperature of >38.3°C (101°F) or a sustained temperature of ≥38°C (100.4°F) for >1 hour |
| 4 | Life-threatening consequences; urgent intervention indicated |
| 5 | Death |
In SOLO-1, these included thrombocytopenia (0.4%), leukopenia (1.5%), and lymphopenia (0.8%).
In SOLO-2, these included thrombocytopenia (1.0%), lymphopenia (0.5%), and leukopenia (1.5%).†
In Study 19, these included pancytopenia (1.5%) and thrombocytopenia (0.7%).‡
In OlympiAD, these included leukopenia (2.5%), lymphopenia (1.0%), and thrombocytopenia (1.5%).
*A disorder characterized by a reduction in the absolute neutrophil count (ANC); associated with a progressively greater risk of infection, and with fever often being the only symptom of infection.30
†Causality due to study drug not assessed.1
‡Investigator-assessed causality.1
The following management strategies were derived from clinical studies that tested LYNPARZA or established medical protocol.
The information on this website is not meant to replace the clinical judgment of the attending physician.
Triage patients with fever seeking emergency medical care ≤6 weeks of receiving chemotherapy; assume that fever with neutropenia is due to an infection if alternative explanation does not exist.
Consider dose interruption
Restart treatment at lower dose when neutropenia is Grade ≤1 or at a maximum of 4 weeks1,10,16-19
Consider dose modification1:
Empirical therapy administered ≤1 hour after triage; patients with febrile neutropenia should receive an intravenous dose of therapy while undergoing evaluation
LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:
For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
In combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either:
Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
For the treatment of adult patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
For the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
For the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
There are no contraindications for LYNPARZA.
Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in <1.5% of patients exposed to LYNPARZA monotherapy, and the majority of events had a fatal outcome. The duration of therapy in patients who developed secondary MDS/AML varied from <6 months to >2 years. All of these patients had previous chemotherapy with platinum agents and/or other DNA-damaging agents, including radiotherapy, and some also had a history of more than one primary malignancy or of bone marrow dysplasia.
Do not start LYNPARZA until patients have recovered from hematological toxicity caused by previous chemotherapy (≤Grade 1). Monitor complete blood count for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities, interrupt LYNPARZA and monitor blood count weekly until recovery.
If the levels have not recovered to Grade 1 or less after 4 weeks, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA if MDS/AML is confirmed.
Pneumonitis: Occurred in <1% of patients exposed to LYNPARZA, and some cases were fatal. If patients present with new or worsening respiratory symptoms such as dyspnea, cough, and fever, or a radiological abnormality occurs, interrupt LYNPARZA treatment and initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is confirmed and treat patient appropriately.
Embryo-Fetal Toxicity: Based on its mechanism of action and findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is recommended for females of reproductive potential prior to initiating treatment.
FemalesAdvise females of reproductive potential of the potential risk to a fetus and to use effective contraception during treatment and for 6 months following the last dose.
Males Advise male patients with female partners of reproductive potential or who are pregnant to use effective contraception during treatment and for 3 months following the last dose of LYNPARZA and to not donate sperm during this time.
Venous Thromboembolic Events: Including pulmonary embolism, occurred in 7% of patients with metastatic castration-resistant prostate cancer who received LYNPARZA plus androgen deprivation therapy (ADT) compared to 3.1% of patients receiving enzalutamide or abiraterone plus ADT in the PROfound study. Patients receiving LYNPARZA and ADT had a 6% incidence of pulmonary embolism compared to 0.8% of patients treated with ADT plus either enzalutamide or abiraterone. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism, and treat as medically appropriate, which may include long-term anticoagulation as clinically indicated.
Most common adverse reactions (Grades 1-4) in ≥10% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for SOLO-1 were: nausea (77%), fatigue (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea (37%), constipation (28%), upper respiratory tract infection/influenza/nasopharyngitis/bronchitis (28%), dysgeusia (26%), decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia (17%), dyspnea (15%), leukopenia (13%), UTI (13%), thrombocytopenia (11%), and stomatitis (11%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for SOLO-1 were: decrease in hemoglobin (87%), increase in mean corpuscular volume (87%), decrease in leukocytes (70%), decrease in lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease in platelets (35%), and increase in serum creatinine (34%).
Most common adverse reactions (Grades 1-4) in ≥10% of patients treated with LYNPARZA/bevacizumab compared to a ≥5% frequency for placebo/bevacizumab in the first-line maintenance setting for PAOLA-1 were: nausea (53%), fatigue (including asthenia) (53%), anemia (41%), lymphopenia (24%), vomiting (22%) and leukopenia (18%). In addition, the most common adverse reactions (≥10%) for patients receiving LYNPARZA/bevacizumab irrespective of the frequency compared with the placebo/bevacizumab arm were: diarrhea (18%), neutropenia (18%), urinary tract infection (15%) and headache (14%).
In addition, venous thromboembolic events occurred more commonly in patients receiving LYNPARZA/bevacizumab (5%) than in those receiving placebo/bevacizumab (1.9%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients for LYNPARZA in combination with bevacizumab in the first-line maintenance setting for PAOLA-1 were: decrease in hemoglobin (79%), decrease in lymphocytes (63%), increase in serum creatinine (61%), decrease in leukocytes (59%), decrease in absolute neutrophil count (35%) and decrease in platelets (35%).
Most common adverse reactions (Grades 1-4) in ≥20% of patients in clinical trials of LYNPARZA in the maintenance setting for SOLO-2 were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%), vomiting (37%), nasopharyngitis/upper respiratory tract infection (URI)/influenza (36%), diarrhea (33%), arthralgia/myalgia (30%), dysgeusia (27%), headache (26%), decreased appetite (22%), and stomatitis (20%).
Study 19: nausea (71%), fatigue (including asthenia) (63%), vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract infection (22%), constipation (22%), headache (21%), decreased appetite (21%) and dyspepsia (20%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA in the maintenance setting (SOLO-2/Study 19) were: increase in mean corpuscular volume (89%/82%), decrease in hemoglobin (83%/82%), decrease in leukocytes (69%/58%), decrease in lymphocytes (67%/52%), decrease in absolute neutrophil count (51%/47%), increase in serum creatinine (44%/45%), and decrease in platelets (42%/36%).
Most common adverse reactions (Grades 1-4) in ≥20% of patients in clinical trials of LYNPARZA for advanced gBRCAm ovarian cancer after 3 or more lines of chemotherapy (pooled from 6 studies) were: fatigue/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%), diarrhea (31%), nasopharyngitis/upper respiratory tract infection (URI) (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and arthralgia/musculoskeletal pain (21%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA for advanced gBRCAm ovarian cancer (pooled from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular volume elevation (57%), decrease in lymphocytes (56%), increase in serum creatinine (30%), decrease in platelets (30%), and decrease in absolute neutrophil count (25%).
Most common adverse reactions (Grades 1-4) in ≥20% of patients in OlympiAD were: nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in OlympiAD were: decrease in hemoglobin (82%), decrease in lymphocytes (73%), decrease in leukocytes (71%), increase in mean corpuscular volume (71%), decrease in absolute neutrophil count (46%), and decrease in platelets (33%).
Most common adverse reactions (Grades 1-4) in ≥10% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for POLO were: fatigue (60%), nausea (45%), abdominal pain (34%), diarrhea (29%), anemia (27%), decreased appetite (25%), constipation (23%), vomiting (20%), back pain (19%), arthralgia (15%), rash (15%), thrombocytopenia (14%), dyspnea (13%), neutropenia (12%), nasopharyngitis (12%), dysgeusia (11%), and stomatitis (10%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA in the first-line maintenance setting for POLO were: increase in serum creatinine (99%), decrease in hemoglobin (86%), increase in mean corpuscular volume (71%), decrease in lymphocytes (61%), decrease in platelets (56%), decrease in leukocytes (50%), and decrease in absolute neutrophil count (25%).
Most common adverse reactions (Grades 1-4) in ≥10% of patients in clinical trials of LYNPARZA for PROfound were: anemia (46%), fatigue (including asthenia) (41%), nausea (41%), decreased appetite (30%), diarrhea (21%), vomiting (18%), thrombocytopenia (12%), cough (11%), and dyspnea (10%).
Most common laboratory abnormalities (Grades 1-4) in ≥25% of patients in clinical trials of LYNPARZA for PROfound were: decrease in hemoglobin (98%), decrease in lymphocytes (62%), decrease in leukocytes (53%), and decrease in absolute neutrophil count (34%).
Anticancer Agents: Clinical studies of LYNPARZA with other myelosuppressive anticancer agents, including DNA-damaging agents, indicate a potentiation and prolongation of myelosuppressive toxicity.
CYP3A Inhibitors: Avoid coadministration of strong or moderate CYP3A inhibitors when using LYNPARZA. If a strong or moderate CYP3A inhibitor must be coadministered, reduce the dose of LYNPARZA. Advise patients to avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during LYNPARZA treatment.
CYP3A Inducers: Avoid coadministration of strong or moderate CYP3A inducers when using LYNPARZA.
Lactation: No data are available regarding the presence of olaparib in human milk, its effects on the breastfed infant or on milk production. Because of the potential for serious adverse reactions in the breastfed infant, advise a lactating woman not to breastfeed during treatment with LYNPARZA and for 1 month after receiving the final dose.
Pediatric Use: The safety and efficacy of LYNPARZA have not been established in pediatric patients.
Hepatic Impairment: No adjustment to the starting dose is required in patients with mild or moderate hepatic impairment (Child-Pugh classification A and B). There are no data in patients with severe hepatic impairment (Child-Pugh classification C).
Renal Impairment: No dosage modification is recommended in patients with mild renal impairment (CLcr 51-80 mL/min estimated by Cockcroft-Gault). In patients with moderate renal impairment (CLcr 31-50 mL/min), reduce the dose of LYNPARZA to 200 mg twice daily. There are no data in patients with severe renal impairment or end-stage renal disease (CLcr ≤30 mL/min).
